Search

Your search keyword '"El-Hariry, Iman A."' showing total 15 results

Search Constraints

Start Over You searched for: Author "El-Hariry, Iman A." Remove constraint Author: "El-Hariry, Iman A." Database Complementary Index Remove constraint Database: Complementary Index
15 results on '"El-Hariry, Iman A."'

Search Results

1. Asparaginase encapsulated in erythrocytes as second‐line treatment in hypersensitive patients with acute lymphoblastic leukaemia.

2. Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.

Catalog

Books, media, physical & digital resources

3. Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials.

4. A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer.

5. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.

6. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region.

7. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

8. Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck.

9. A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.

10. A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma.

14. Erratum to: Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.

15. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.